# Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization

Study · id `cardio:ct-nct07616544` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07616544](<https://clinicaltrials.gov/study/NCT07616544>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07616544

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 164 participants.

## Technical summary

Registry record NCT07616544. Randomized; triple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 164 participants (planned count; ClinicalTrials.gov record NCT07616544, source copy `cardio:ctgov-nct07616544-2026-06-01`, retrieved 2026-10-26)
- Planned start: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT07616544, source copy `cardio:ctgov-nct07616544-2026-06-01`, retrieved 2026-10-26)
- Primary completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07616544, source copy `cardio:ctgov-nct07616544-2026-06-01`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07616544, source copy `cardio:ctgov-nct07616544-2026-06-01`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07616544-2026-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization
- Condition: Percutaneous Coronary Intervention
- Condition: Myocardial Revascularization
- Condition: Coronary Artery Disease
- Intervention (Drug): Qidan Xiaoke Granules + Standard Medical Therapy
- Intervention (Drug): Placebo + Standard Medical Therapy
- Lead sponsor: Liu Qiang
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 447f78e5557a643584188324e6dc1071acc60901bd846b2314d05c3c1d0f73a3
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
